N-Arachidonoyl dopamine

N-Arachidonoyl dopamine (NADA) is a lipid and endocannabinoid that was first described in 2000. It is a neurotransmitter in the central nervous system and is involved in various physiological processes.

Structure and Synthesis

NADA is a fatty acid amide that is structurally similar to other endocannabinoids such as anandamide and 2-arachidonoylglycerol. It is synthesized from arachidonic acid and dopamine by the enzyme fatty acid amide hydrolase (FAAH).

Function

NADA acts as a ligand for the cannabinoid receptor CB1 and the vanilloid receptor TRPV1. It has been shown to have neuroprotective effects and to modulate immune system responses. NADA also plays a role in pain perception and thermoregulation.

Research

Research on NADA has focused on its potential therapeutic applications. Studies have suggested that NADA may have anti-inflammatory and anti-nociceptive effects, and it has been proposed as a potential treatment for conditions such as multiple sclerosis and Parkinson's disease.

See also

• Endocannabinoid system
• Cannabinoid receptor
• Vanilloid receptor